Results 251 to 260 of about 233,436 (339)

Prospective, Multicenter Evaluation of Transcarotid Artery Revascularization in Standard‐Risk Patients: 30‐Day Outcomes of the ROADSTER 3 Study

open access: yesAnnals of Neurology, EarlyView.
Objective To evaluate the real‐world safety and efficacy for standard surgical risk patients with extracranial internal carotid artery disease undergoing transcarotid artery revascularization. Methods ROADSTER 3 is a prospective, multicenter, single‐arm post‐approval study.
Jeffrey Jim   +15 more
wiley   +1 more source

The Role of miRNAs in Chicken Immune Regulation and Prospects for Disease‐Resistant Breeding

open access: yesAnimal Research and One Health, EarlyView.
A schematic workflow illustrating the screening of disease‐resistant miRNAs and the generation of miRNA‐based disease‐resistant chickens via PGC‐mediated germline genome editing. ABSTRACT MicroRNAs (miRNAs) are emerging as pivotal regulators of the immune system, playing a decisive role in shaping disease resistance in chicken.
Qiangzhou Wang   +10 more
wiley   +1 more source

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani   +4 more
wiley   +1 more source

A retrospective study of the short-term complication rate following 750 elective elbow arthroscopies [PDF]

open access: yes, 2014
Burton   +9 more
core   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy